Comparative Pharmacology
Head-to-head clinical analysis: ALEVE versus IBUPRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALEVE versus IBUPRIN.
ALEVE vs IBUPRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, resulting in anti-inflammatory, analgesic, and antipyretic effects.
220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.
200-800 mg orally every 6-8 hours as needed; maximum daily dose 3200 mg.
None Documented
None Documented
Terminal elimination half-life is 12-17 hours; allows twice-daily dosing for steady-state concentrations.
Terminal elimination half-life is approximately 2-4 hours; in elderly or patients with hepatic impairment, half-life may be prolonged to 6-8 hours.
Renal (95% as unchanged drug and metabolites); biliary/fecal (5%)
Renal excretion of conjugated metabolites (75-85%), with less than 10% excreted unchanged; biliary/fecal elimination accounts for less than 10%.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)